PolandPoland

Selvita And Orion Pharma co-develop Alzheimer compound

09.07.2010

Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to the global development and marketing agreement, Selita will receive an initial up-front payment from Orion, as well as research funding and milestones. Selvita will be responsible for compound screening and selection on the programme and Orion will take over the pre-clinical and clinical development as well as further commercialisation. The companies are planning to conduct a broad-based global research and development programme which will combine the resources of Orion’s experienced CNS research and development team with Selvita’s competencies in discovery chemistry and biology assays.

PolandPoland

21.02.2009

Kraków – According to a report from Kraków-based PMR Ltd, the Czech Republic and Poland are on top in eastern Europe when it comes to outsourcing clinical trials and contract manufacture. The market analysis outlines 160...

PolandPoland

21.02.2009

Szczecin – The West-Pomeranian Center for Advanced Technologies and the German regional cluster BioCon Valley are setting up a German-Polish contact point for the life sciences. The long-term goal of the cooperation, which will...

PolandPoland

21.02.2009

Raszyn Rybie – Polish Euroimplant S.A. has received a66,000 in funding from the National Center for Research and Development (NCBiR) for product development, according to CE.biotech.com. The specialist firm for tissue...

PolandPoland

21.02.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its mana­gement board after announcing that an expected deal failed to materialise. In mid-January, after Prokom Investments (Gdynia) proved unable to sell...

PolandPoland

21.02.2009

Kraków – BioCentrum Sp. zo.o. is expanding contract research activities for the bio-pharmaceutical industry. In December, the Polish specialist for preclinical ADME, cell-based assays, protein characterisation, antibody, enzyme...

PolandPoland

23.01.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its management board after a failed deal hit the news. When Prokom Investments (Gdynia) failed to sell a 33.3% stake in Bioton to Jerzy Starak’s Polpharma for...

PolandPoland

11.11.2008

Warsaw – In August, the lower chamber of the Polish parliament approved a 31m EUR programme for the protection of mental health to run from 2009-2013. The programme, which is to be financed from the state budget and EU funds,...

PolandPoland

18.08.2008

Portoroz – Around 120 international bioprocessing experts met at the 3rd Monolith Summer Symposium at Portoroz to discuss how monolith chromatography can eliminate current bottlenecks in downstream processing of biological drugs....

PolandPoland

20.05.2008

Krakow – Selvita Sp. z o.o., a newly founded service provider to the biotechnological and pharmaceutical industries, has taken over biotech tools and services supplier BioCentrum Ltd. At the end of March, Selvita acquired 64% of...

PolandPoland

20.05.2008

Warsaw – Together with the top ten Polish universities, one hundred Polish technology companies have kicked-off a business chamber for advanced technology (PIGZT). The chamber will provide a platform for improving information...

Displaying results 31 to 40 out of 108

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/3/article/selvita-and-orion-pharma-co-develop-alzheimer-compound.html

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF111.2%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR98.1%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.8%
  • MERCK KGAA (D)63.67 EUR-50.5%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • IXICO (UK)55.50 GBP314.2%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.0%

No liability assumed, Date: 10.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events